Merck and the Mayo Clinic have announced a strategic R&D agreement to integrate artificial intelligence, advanced analytics, and multimodal clinical data into the drug development pipeline. The partnership aims to utilize AI-enabled virtual cell technologies to enhance disease understanding and streamline early-stage decision-making.
The collaboration features several key technical pillars:
-
Data Integration: Merck will leverage the Mayo Clinic Platform to access de-identified clinical and genomic datasets, including medical imaging, lab results, and molecular data from a global partner network.
-
Therapeutic Focus: Initial research will target high-need areas in three specialties: Gastroenterology (Inflammatory Bowel Disease), Dermatology (Atopic Dermatitis), and Neurology (Multiple Sclerosis).
-
Technological Goals: The agreement focuses on using machine learning (ML) for computational and spatial biology to improve target identification and the overall probability of clinical success.
By utilizing the “Mayo Clinic Platform_Orchestrate” program, Merck gains direct access to clinical expertise and biorepositories to validate its AI models. This initiative reflects a broader shift toward platform-based collaboration in healthcare, where real-world evidence and AI foundation models are used to redefine how innovative breakthroughs are discovered and scaled for patients worldwide.